NES Transdermal Spray
Alternative Name: Nestorone (NES) Metered Dose Transdermal System® (MDTS®)
Description: A transdermal spray, using the Metered Dose Transdermal System developed by Acrux, Ltd., containing nestorone (NES) and potentially an estrogen (either EE or E2). The spray delivers drugs to the skin surface and with the aid of safe enhancers, forms a reservoir within the skin from which the drug is slowly absorbed into circulation over a period of many hours (up to 72 hours).
Product Details
Duration: One day
Regimen:
Active Pharmaceutical Ingredient (API):
Status Details
Developer: , ,
Began discovery in: 2003
Status Details: - The company developing the spray was no longer interested in developing the formulation and abandoned the project.
- The company developing the spray was no longer interested in developing the formulation and abandoned the project.
Additional Information
References: Fraser IS. (2007) An initial pharmacokinetic study with a Metered Dose Transdermal System for delivery of the progestogen Nestorone as a possible future contraceptive. Contraception 76(6):432-8.
Updated by Sarah 07/06/2018 based on web-search.
Fraser IS. (2007) An initial pharmacokinetic study with a Metered Dose Transdermal System for delivery of the progestogen Nestorone as a possible future contraceptive. Contraception 76(6):432-8.
Updated by Sarah 07/06/2018 based on web-search.